
The panel discusses strategies for managing toxicity and optimizing treatment duration with BCMA-directed therapies in relapsed/refractory multiple myeloma.

Hans Lee, MD, is the director of Myeloma Research at the Sarah Cannon Research Institute

The panel discusses strategies for managing toxicity and optimizing treatment duration with BCMA-directed therapies in relapsed/refractory multiple myeloma.

The panel discusses supportive care strategies for safely administering BCMA-directed therapies in relapsed/refractory multiple myeloma, with particular attention to bispecific antibodies and belantamab mafodotin.

The panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.

The panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.

The panel discusses how clinicians may differentiate among BCMA-directed bispecific antibodies as the treatment landscape becomes increasingly crowded.

The panel discusses the movement of BCMA-directed therapies from relapsed/refractory multiple myeloma into earlier-line and newly diagnosed disease.

Dr. Hans Lee and the panel discuss emerging combination strategies and treatment sequencing for patients with relapsed/refractory multiple myeloma.

The panel discusses geographic access, community-based treatment, and evolving guideline recommendations for BCMA-directed therapies in relapsed/refractory multiple myeloma.

The panel discusses the practical advantages of off-the-shelf BCMA-directed therapies in relapsed/refractory multiple myeloma, particularly for patients with rapidly progressing disease or high disease burden who may not be able to wait for CAR T-cell manufacturing.

Dr. Hans Lee and Dr. Douglas Sborov discuss how clinical trial subgroup data can inform treatment selection for patients with high-risk relapsed/refractory multiple myeloma.

Dr. Paul Richardson discusses clinical data and practical considerations for belantamab mafodotin as a BCMA-directed antibody-drug conjugate in relapsed/refractory multiple myeloma, highlighting findings from the DREAMM-7 study.

Dr. Hans Lee and Dr. Jing Christine Ye discuss the evolution of clinical data for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma, focusing on the increasing understanding of response depth and durability with longer follow-up.

The panel concludes by sharing practical takeaways for clinicians managing patients with multiple myeloma.

Dr. Hans Lee and Dr. Douglas Sborov discuss how clinicians conceptualize the three major BCMA-directed treatment approaches in relapsed/refractory multiple myeloma: CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.

The discussion opens with an overview of the rapidly evolving treatment landscape in relapsed/refractory multiple myeloma, highlighting the expanding range of BCMA-directed therapeutic approaches.

The panel looks ahead to the next 3 to 5 years of multiple myeloma treatment, highlighting emerging strategies that could further reshape the treatment landscape.

Dr. Hans Lee and Dr. Prashant Kapoor discuss strategies to expand access to CAR T-cell therapies and bispecific antibodies for patients with multiple myeloma, particularly in community oncology settings.

Dr. Hans Lee and Dr. Muhamed Baljevic discuss the emerging role of bispecific antibodies in frontline treatment for newly diagnosed multiple myeloma, focusing on data from the MajesTEC-5 study and other ongoing investigations.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the potential role of talquetamab-based therapy in the evolving treatment sequence for relapsed/refractory multiple myeloma.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss treatment strategies for patients with multiple myeloma who relapse following BCMA-directed CAR T-cell therapy or bispecific antibodies.

Dr. Hans Lee, Dr. Prashant Kapoor, and Dr. Muhamed Baljevic discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, including its use across transplant-eligible and transplant-ineligible populations.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss supportive care considerations for patients receiving T-cell redirecting therapies, with a focus on infection prevention and mitigation of cytokine release syndrome (CRS) during bispecific antibody step-up dosing.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss evolving treatment strategies for early relapse and relapsed/refractory multiple myeloma, focusing on recent evidence for T-cell redirecting therapies.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss individualized treatment selection and sequencing in multiple myeloma as increasingly effective therapies expand available options.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the evolving role of treatment duration and de-escalation in multiple myeloma, particularly for patients who achieve deep and sustained responses.

In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life.

In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease.

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.

Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.

Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.